School of Pharmacy

Isabelle Ragueneau-Majlessi

Clinical Professor

Department of Pharmaceutics, Pharmaceutics Faculty

Telephone: (206) 543-4669


Office Location: 4225 Roosevelt Way NE Suite 305 Suite 305 Seattle, WA 98105

Website: PubMed

Research interests

Mechanistic aspects, clinical relevance, and risk management of drug-drug interaction (DDI). Regulatory framework of DDI assessment.


Dr. Ragueneau received her medical degree in 1993 from St Antoine University in Paris, France, and specialized in Clinical Pharmacology. Dr Ragueneau designed and supervised clinical studies both in the private sector, as Project Manager at SERVIER (1992-1994), and in academia, in the Clinical Pharmacology Unit of St Antoine Hospital in Paris (1994-1998). She started working at the University of Washington in early 1999, as Research Associate (1999-2005), then Principal Research Scientist (2005-2009) and Project Manager for the School of Pharmacy’s Metabolism and Transport Drug Interaction Database. In November 2009, Dr. Ragueneau joined the Faculty of the Department of Pharmaceutics and became Director of the Drug Interaction Database program. She currently supervises a team of research scientists (PhD, PharmD levels) and IT developers. Dr. Ragueneau has published in the areas of drug-drug interactions (DDIs), drug disposition and clinical pharmacology. She is interested in the regulatory framework of DDI assessment and the clinical relevance of drug interactions. Dr. Ragueneau also graduated from the University of Washington’s Master’s Degree Program in Biomedical Regulatory Affairs in 2010.

Selected Publications

Lee CA, O’Connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-Majlessi I, Ellens H, Feng B, Taub ME, Paine MF, Polli JW, Ware JA, Zamek-Gliszczynski MJ. Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design. Drug Metab Dispos. 2015 Apr;43(4):490-509.

Yu J, Ritchie TK, Mulgaonkar A, Ragueneau-Majlessi I. Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review. Drug Metab Dispos. 2014 Dec;42(12):1991-2001.

Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V, Fretland A, Grime K, Hall SD, Higgs R, Plowchalk D, Riley R, Seibert E, Skordos K, Snoeys J, Venkatakrishnan K, Waterhouse T, Obach RS, Berglund EG, Zhang L, Zhao P, Reynolds KS, Huang SM. Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug. Clin Pharmacol Ther. 2014 Feb;95(2):189-98.

Ellens H, Deng S, Coleman J, Bentz J, Taub ME, Ragueneau-Majlessi I, Chung SP, Herí di-Szabí_ K, Neuhoff S, Palm J, Balimane P, Zhang L, Jamei M, Hanna I, O’Connor M, Bednarczyk D, Forsgard M, Chu X, Funk C, Guo A, Hillgren KM, Li L, Pak AY, Perloff ES, Rajaraman G, Salphati L, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yamagata T, Lee CA. Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions. Drug Metab Dispos. 2013 Jul;41(7):1367-74.

Hazai E, Hazai I, Ragueneau-Majlessi I, Chung SP, Bikadi Z, Mao Q. Predicting substrates of the human breast cancer resistance protein using a support vector machine method. BMC Bioinformatics. 2013 Apr 15;14:130.

Isoherranen N, Lutz JD, Chung SP, Hachad H, Levy RH, Ragueneau-Majlessi I. Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data. Chem Res Toxicol. 2012 Nov 19;25(11):2285-300.

Hachad H, Overby CL, Argon S, Yeung CK, Ragueneau-Majlessi I, Levy RH. e-PKGene: a knowledge-based research tool for analysing the impact of genetics on drug exposure. Hum Genomics. 2011 Jul;5(5):506-15.

Hachad H, Ragueneau-Majlessi I, Levy RH. A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database. Hum Genomics. 2010 Oct;5(1):61-72.

Zhang H, Ragueneau-Majlessi I, Levy RH. Interaction Between Clopidogrel and Proton Pump Inhibitors: Hypothesis to Explain Multifactorial CYP2C19 Inhibition. Drug Metab Lett. 2009 Dec;3(4):287-9.

Hachad H, Ragueneau-Majlessi I, Levy RH. Management of Drug Interactions of New Drugs in Multicenter Trials using the Metabolism & Transport Drug Interaction DatabaseΩ. Chapter 15. Enzymatic- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges. Edited by D Rodrigues (2010).

Zhao P, Ragueneau-Majlessi I, Zhang L, Strong J, Reynolds KS, Levy RH, Thummel KE, Huang SM. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 2009 Mar;49(3):351-9.